John A. Moran Eye Center’s Voyant Biotherapeutics, LLC Enters Into Exclusive R&D Collaboration Agreement With Allergan Inc. (AGN)
2/21/2014 9:02:31 AM
SALT LAKE CITY--(BUSINESS WIRE)--The John A. Moran Eye Center at the University of Utah today announced that Voyant Biotherapeutics, LLC, a company formed out of its Center for Translational Medicine (CTM), has signed an exclusive R&D Collaboration Agreement with Allergan, Inc. (NYSE: AGN), a multispecialty health care company headquartered in Irvine, Calif. The agreement provides for a combination of upfront, research and milestone payments. Under the agreement, the two companies will work together to identify disease-associated pathways and targets for the development of new therapeutic agents to treat ocular disease. A primary effort of this collaboration will be centered on new treatments for age-related macular degeneration (AMD), a leading cause of irreversible vision loss worldwide.
Help employers find you! Check out all the jobs and post your resume.
comments powered by